Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
To design and direct at will the specificity of T cells in a non-major histocompatibility complex (MHC)-restricted manner, we have generated and expressed chimeric T-cell receptor (TcR) genes composed of the TcR constant (C) domains fused to the antibody's variable (V) domains. Genomic expression vectors have been constructed containing the rearranged gene segments coding for the V region domains of the heavy (VH) and light (VL) chains of an anti-2,4,6-trinitrophenyl (TNP) antibody (SP6) spliced to either one of the C-region gene segments of the alpha or beta TcR chains. Following transfection into a cytotoxic T-cell hybridoma, expression of a functional TcR was detected. The chimeric TcR exhibited the idiotope of the Sp6 anti-TNP antibody and endowed the T cells with a non-MHC-restricted response to the hapten TNP. The transfectants specifically killed and produced interleukin 2 in response to TNP-bearing target cells across strain and species barriers. Moreover, such transfectants responded to immobilized TNP-protein conjugates, bypassing the need for cellular processing and presentation. In the particular system employed, both the TNP-binding site and the Sp6 idiotope reside almost exclusively in the VH chain region. Hence, introduction into T cells of TcR genes containing only the VHSp6 fused to either the C alpha or C beta was sufficient for the expression of a functional surface receptor. Apparently, the VHC alpha or VHC beta chimeric chains can pair with the endogenous beta or alpha chains of the recipient T cell to form a functional alpha beta heterodimeric receptor. Thus, this chimeric receptor provides the T cell with an antibody-like specificity and is able to effectively transmit the signal for T-cell activation and execution of its effector function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Southern, P. J., & Berg, P. R. (1982) · PubMed · Cited by 3,086
Mulligan, R. C., & Berg, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2072 · Cited by 982
Schwartz, R. (1985) · Annual Review of Immunology · doi:10.1146/annurev.immunol.3.1.237 · Cited by 932
The Molecular Genetics of the T-Cell Antigen Receptor and T-Cell Antigen Recognition
Kronenberg, M. (1986) · Annual Review of Immunology · doi:10.1146/annurev.immunol.4.1.529 · Cited by 765
Rusconi, S., & Köhler, G. (1985) · Nature · doi:10.1038/314330a0 · Cited by 239
Cited by
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Self-citationCancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
Global Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
Metastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 669
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
T cell-engaging therapies — BiTEs and beyond
Goebeler, M.-E., & Bargou, R. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0347-5 · Cited by 644
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
Feins, S., Kong, W., Williams, E. F., Milone, M. C., & Fraietta, J. A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25418 · Cited by 614
T cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 604
Cancer Immunotherapy Comes of Age
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586
Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
“The presence of the native CD3zeta transmembrane can cause the incorporation of the artificial TCR into the native TCR.”
InfluentialDifferent Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
Golubovskaya, V., & Wu, L. (2016) · Cancers · doi:10.3390/cancers8030036 · Cited by 577
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Moon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Kalos, M., & June, C. H. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.002 · Cited by 486
Next-generation regulatory T cell therapy
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A., & Tang, Q. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0041-4 · Cited by 476
From bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 466
The Intriguing History of Cancer Immunotherapy
Dobosz, P., & Dzieciątkowski, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02965 · Cited by 458
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 446
Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0020 · Cited by 426
Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V, Morrissette, J. J. D., Scholler, J., Song, D., Porter, D. L., Carroll, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 426
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
Kochenderfer, J. N., Feldman, S. A., Zhao, Y., Xu, H., Black, M. A., Morgan, R. A., Wilson, W. H., & Rosenberg, S. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ac6138 · Cited by 408
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
Porter, D., Frey, N., Wood, P. A., Weng, Y., & Grupp, S. A. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0571-y · Cited by 401
Adoptive cellular therapies: the current landscape
Rohaan, M. W., Wilgenhof, S., & Haanen, J. B. A. G. (2019) · Virchows Archiv · doi:10.1007/s00428-018-2484-0 · Cited by 398
Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides
Romeo, C., & Seed, B. (1991) · Cell · doi:10.1016/0092-8674(91)90327-u · Cited by 396
Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Blood · doi:10.1182/blood-2010-01-265041 · Cited by 391
Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Rosenberg, S. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.180 · Cited by 390
A guide to manufacturing CAR T cell therapies
Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 383
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
Yakoub-Agha, I., Chabannon, C., Bader, P., Basak, G. W., Bonig, H., Ciceri, F., Corbacioglu, S., Duarte, R. F., Einsele, H., Hudecek, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.229781 · Cited by 365
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
Song, D.-G., Ye, Q., Poussin, M., Harms, G. M., Figini, M., & Powell, D. J. (2012) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 355
Gene therapy: advances, challenges and perspectives
Gonçalves, G. A. R., & Paiva, R. D. M. A. (2017) · Einstein (São Paulo) · doi:10.1590/s1679-45082017rb4024 · Cited by 351
“,(16) was marked by the fusion of a single chain fragment variable (scFv) to a transmembrane domain and an intracellular signaling unit: chain CD3 zeta.(17,18) This design combined the active element of a well-characterized monoclonal antibody with a signaling domain, increasing the recognition of the tumor-specific e…”
BackgroundSantomasso, B., Bachier, C., Westin, J., Rezvani, K., & Shpall, E. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238691 · Cited by 330
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Weinkove, R., George, P., Dasyam, N., & McLellan, A. D. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1049 · Cited by 324
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Guest, R. D., Hawkins, R. E., Kirillova, N., Cheadle, E. J., Arnold, J., O'Neill, A., Irlam, J., Chester, K. A., Kemshead, J. T., Shaw, D. M., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000161397.96582.59 · Cited by 318
Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
Rosenberg, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.116 · Cited by 312
Harnessing the immune system to improve cancer therapy
Papaioannou, N. E., Beniata, O. V., Vitsos, P., Tsitsilonis, O., & Samara, P. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.04.01 · Cited by 307
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
Jena, B., Dotti, G., & Cooper, L. J. N. (2010) · Blood · doi:10.1182/blood-2010-01-043737 · Cited by 297
Tertiary lymphoid structures in anticancer immunity
Teillaud, J.-L., Houel, A., Panouillot, M., Riffard, C., & Dieu-Nosjean, M.-C. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 293
Zhang, W., Liu, L., Su, H., Liu, Q., Shen, J., Dai, H., Zheng, W., Lu, Y., Zhang, W., Bei, Y., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0578-3 · Cited by 291
Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Ruella, M., & Maus, M. V. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.003 · Cited by 285
An early history of T cell-mediated cytotoxicity
Golstein, P., & Griffiths, G. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0009-3 · Cited by 284
Siegler, E. L., & Kenderian, S. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01973 · Cited by 282
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Synthetic biology in mammalian cells: next generation research tools and therapeutics
Lienert, F., Lohmueller, J. J., Garg, A., & Silver, P. A. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3738 · Cited by 280
Vera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., Wu, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017061 · Cited by 275
Driving gene-engineered T cell immunotherapy of cancer
Johnson, L. A., & June, C. H. (2017) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 268
Hu, W., Zi, Z., Jin, Y., Li, G., Shao, K., Cai, Q., Ma, X., & Wei, F. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2281-2 · Cited by 265
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
Novel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 260
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Tamada, K., Geng, D., Sakoda, Y., Bansal, N., Srivastava, R., Li, Z., & Davila, E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1449 · Cited by 259
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Mehta, R. S., & Rezvani, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00283 · Cited by 259
Designing customized cell signalling circuits
Lim, W. A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2904 · Cited by 257
Cell Therapy: Types, Regulation, and Clinical Benefits
El-Kadiry, A. E.-H., Rafei, M., & Shammaa, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756029 · Cited by 256
“CAR-T cells are functionally similar to TCR gene therapy yet function in a non–MHC-restricted manner (132).”
BackgroundHwu, P., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A., & Eshhar, Z. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.1.361 · Cited by 256
Self-citationIntegrating Biological Redesign: Where Synthetic Biology Came From and Where It Needs to Go
Way, J. C., Collins, J. J., Keasling, J. D., & Silver, P. A. (2014) · Cell · doi:10.1016/j.cell.2014.02.039 · Cited by 252
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 244
Watanabe, K., Kuramitsu, S., Posey, A. D., & June, C. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02486 · Cited by 242
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 229
“This fusion of the antibody-derived single chain variable fragment with the T cell intracellular signaling domains endows the CAR T cell with the ability to recognize the tumor antigen in a non-MHC-restricted manner [140].”
BackgroundPriem, B., van Leent, M. M. T., Teunissen, A. J. P., Sofias, A. M., Mourits, V. P., Willemsen, L., Klein, E. D., Oosterwijk, R. S., Meerwaldt, A. E., Munitz, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.059 · Cited by 222
Tettamanti, S., Marin, V., Pizzitola, I., Magnani, C. F., Giordano Attianese, G. M. P., Cribioli, E., Maltese, F., Galimberti, S., Lopez, A. F., Biondi, A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12282 · Cited by 211
“Notably, even though the efficacy of CAR-redirected T cells has been largely demonstrated (Gross et al, 1989; Biagi et al, 2007, 2011; Kohn et al, 2011), particularly targeting the CD19 antigen on B-lymphoid origin malignancies, this approach is not devoid of safety concerns, given that serious…”
BackgroundCAR-T cell performance: How to improve their persistence?
López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878209 · Cited by 207
“, an extracellular single-chain variable fragment (scFv) specific for a cancer marker; hinge and transmembrane regions usually derived from the CH2– CH3 region of IgG1, IgG4, or CD8; and the cytoplasmic CD3z signaling domain (Figure 3A) (76, 77).”
BackgroundGuo, X., Jiang, H., Shi, B., Zhou, M., Zhang, H., Shi, Z., Du, G., Luo, H., Wu, X., Wang, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01118 · Cited by 206
Engineering lymphocyte subsets: tools, trials and tribulations
June, C. H., Blazar, B. R., & Riley, J. L. (2009) · Nature Reviews Immunology · doi:10.1038/nri2635 · Cited by 204
“Since being first reported in mice more than two decades ag”
BackgroundCAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Wang, J., Chen, S., Xiao, W., Li, W., Wang, L., Yang, S., Wang, W., Xu, L., Liao, S., Liu, W., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0553-5 · Cited by 201
Nakagawara, A., Li, Y., Izumi, H., Muramori, K., Inada, H., & Nishi, M. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx176 · Cited by 197
“CAR-T therapy was first reported by Gross and colleagues from Israel (357).”
HLA-independent T cell receptors for targeting tumors with low antigen density
Mansilla-Soto, J., Eyquem, J., Haubner, S., Hamieh, M., Feucht, J., Paillon, N., Zucchetti, A. E., Li, Z., Sjöstrand, M., Lindenbergh, P. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01621-1 · Cited by 190
CAR T-Cell Therapy in Hematological Malignancies
Haslauer, T., Greil, R., Zaborsky, N., & Geisberger, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168996 · Cited by 180
“This technique was first demonstrated by the Eshhar lab, which paved the way for a chimeric cancer therapy [4].”
MethodFrom concept to cure: The evolution of CAR-T cell therapy
Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N., & June, C. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.005 · Cited by 180
CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe
Gilham, D. E., Debets, R., Pule, M., Hawkins, R. E., & Abken, H. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.04.009 · Cited by 179
Mechanism of Action of Immunotherapy
Disis, M. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.004 · Cited by 175
CAR T-cell therapy in hematologic malignancies: a voyage in progress.
Holstein, S. A., & Lunning, M. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1674 · Cited by 172
“However, as it is difficult to culture tumor-reactive T-cells, the field progressed to the engineering of T cells expressing tumorantigen-specific TCRs(7) and then to chimeric antigen receptors (CARs).(8,9) CARs are composed of an antigen-recognizing receptor coupled to signaling molecules that lead to activated T cel…”
BackgroundPark, S., Shevlin, E., Vedvyas, Y., Zaman, M., Park, S., Hsu, Y.-M. S., Min, I. M., & Jin, M. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14749-3 · Cited by 163
“The advantages of CAR mediated targeting include: (1) the provision of activation, proliferation, and survival signals in-cis via a single binding event, compared to the natural, non-integrated TCR and costimulatory signaling; (2) the ability to bypass the downregulation of major histocompatibility complex (MHC) by tu…”
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
“were the first to construct the CAR-T cells for the expression of antigen receptors.(263) The intracellular structural domain of first-generation CAR-T cells contains only the signal transduction structural domain CD3-ζ, so that CAR-T cells have poor proliferative abilities and a short survival time in vivo, due to th…”
BackgroundImmunotherapeutic approaches to treatment of fungal diseases
Armstrong-James, D., Brown, G. D., Netea, M. G., Zelante, T., Gresnigt, M. S., van de Veerdonk, F. L., & Levitz, S. M. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30442-5 · Cited by 135
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities
Roybal, K. T., & Lim, W. A. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052302 · Cited by 124
Strategies to enhance CAR-T persistence
Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., & Zhang, X. (2022) · Biomarker Research · doi:10.1186/s40364-022-00434-9 · Cited by 97
“designed a chimeric T-cell receptor (TCR) gene consisting of the TCR constant domain and the antibody variable domain and transfected it into cytotoxic T cells, conferring these T cells with antibody-like specificity [1].”
Background
Metadata
- Authors
- Gross, G., Waks, T., & Eshhar, Z.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1989-12
- Volume
- 86
- Issue
- 24
- Pages
- 10024-10028
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2047205338
- Cited by
- 1,590
- References
- 17
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.